Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$0.34
$0.01(4.36%)
At close: 4:00 PM EDT
$0.34
$0.01(4.36%)
Day’s Range― - ―
52-Week Range$1.00 - $123.76
Previous Close$0.3
Volume246.34K
Average Volume (3M)2.90M
Market Cap
$1.05M
Enterprise Value$2.43M
Total Cash (Recent Filing)$1.12M
Total Debt (Recent Filing)$19.00K
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-180.45
Shares Outstanding1,018,017
10 Day Avg. Volume558,445
30 Day Avg. Volume2,903,693
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap2.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-56.58
Enterprise Value/Ebitda-0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal Absolute DebtVery low absolute debt reduces immediate debt-servicing pressure and limits the interest burden on a company still funding development. This provides some financial flexibility relative to a highly leveraged structure, although equity volatility and losses remain important constraints.
Debt-reducing Equity FinancingUsing new equity proceeds primarily to reduce debt can improve the capital structure and lower near-term repayment pressure. The remaining funds also support working capital, potentially extending operating capacity as the company advances its diabetes monitoring and biopharmaceutical programs.
Simplified LT-100 Treatment StrategyA single-injection regimen could reduce treatment burden for patients and simplify trial logistics compared with a historical approach requiring up to 15 intradermal injections. If validated clinically, the strategy may improve product usability and support future development efficiency.
Bears Say
No Demonstrated Commercialization TractionZero reported revenue alongside persistent, widening losses indicates that the company has not yet demonstrated commercial traction from its glucose-monitoring or broader platform activities. Continued development without an established revenue base weakens operating self-sufficiency and raises execution risk.
Accelerating Cash BurnConsistently negative and worsening operating cash flow shows that ongoing operations consume substantial cash rather than funding themselves. The accelerating burn increases dependence on external capital, reduces resilience during development setbacks, and can force financing before programs generate meaningful returns.
Convertible Financing And Dilution ExposureThe company remains reliant on capital markets, while secured convertible notes add repayment obligations, interest expense, and potential share dilution. Warrants and conversion features can expand the equity base, limiting existing holders’ ownership and leaving the company exposed to refinancing pressure.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $1.00 and its highest was $123.76 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $1.05M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is Nov 12, 2026 which is in 31 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on Aug 13, 2026. The company reported -$11.421 earnings per share for the quarter.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 1,018,017 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$11.421 in its last earnings report. Following the earnings report the stock price went down -3.008%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Technical Analysis
Ownership Overview
― Insiders
1.08% Mutual Funds
― Other Institutional Investors
98.92% Public Companies and
Individual Investors